Physician profile
Paula-Ann M Francis
NPI 1760548028
$4,665.22
in general payments reported to CMS, 2019-2025
23 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Forensic Psychiatry provider received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $650 · 2021: $989 · 2022: $732 · 2023: $787 · 2024: $661 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $922.74 | 2019-2025 | Spravato |
| Neuronetics, INC. | $775.47 | 2019-2024 | Neurostar Tms Therapy System |
| Lundbeck LLC | $463.18 | 2019-2024 | Rexulti |
| Abbvie INC. | $372.63 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.94 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $317.68 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $241.37 | 2020-2022 | |
| Livanova USA, INC. | $201.06 | 2022-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Neurocrine Biosciences, INC. | $199.52 | 2024 | Ingrezza |
| Allergan, INC. | $112.02 | 2020 | |
| Adlon Therapeutics L.P. | $111.45 | 2020-2021 | |
| Bausch Health US, LLC | $108.52 | 2022-2024 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $101.00 | 2022-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $93.41 | 2019-2024 | Austedo Xr |
| Almatica Pharma LLC | $82.18 | 2021-2023 | Sertraline Hcl, Loreev Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $59.31 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $43.42 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.05 | 2022-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $27.94 | 2020-2021 | |
| Corium, LLC | $22.53 | 2024 | Azstarys |
| Tris Pharma INC | $21.41 | 2023 | Dyanavel Xr |
| Alkermes, INC. | $14.86 | 2024 | Aristada, Lybalvi |
| Eisai INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula-Ann Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.